Understand the source comparison
Ipamorelin for Growth Hormone Release: Secretagogue Comparison
The table below compares ipamorelin to other commonly used growth hormone secretagogues across receptor selectivity, side effect profiles, and practical research considerations. This comparison is based on peer-reviewed pharmacological studies and clinical tri
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- The table below compares ipamorelin to other commonly used growth hormone secretagogues across receptor selectivity, side effect profiles, and practical research considerations. This comparison is based on peer-reviewed pharmacological studies and clinical trial data published between 2004–2023.
- | Secretagogue | GH Release Potency (vs Baseline) | Cortisol Elevation | Prolactin Elevation | Desensitization Risk | Administration Route | Bottom Line ||—|—|—|—|—|—|| Ipamorelin | 8–13× baseline at 200–300 mcg | None (< 5% change) | None (< 5% change) | Low—stable response through 12 weeks | Subcutaneous injection | Highest selectivity for GH release without hormonal confounds; ideal for metabolic and body composition research || GHRP-6 | 10–15× baseline at 100 mcg | Moderate (+40–60%) | Moderate (+35–50%) | Low | Subcutaneous injection | Potent GH release but significant appetite stimulation and cortisol co-secretion limit research utility || GHRP-2 | 12–18× baseline at 100 mcg | High (+60–90%) | Moderate (+30–45%) | Low | Subcutaneous injection | Strongest peptide GH response but cortisol elevation introduces metabolic confounds || Hexarelin | 15–22× baseline at 100 mcg | Moderate (+50–70%) | High (+60–80%) | High—blunted response after 2–3 weeks | Subcutaneous injection | Maximum